A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Methamphetamine Dependence, Treatment Seeking

In brief

This clinical trial will compare 10 week treatment with acamprosate (2 gr/day) versus placebo, combined with weekly abstinence oriented individual counseling, in methamphetamine dependent patients, 72 subjects will be enrolled, with an interim analysis scheduled after 36 enrolled. Primary outcome is methamphetamine absitience over the 10 week treatment period, and the last 2 weeks of treatment. Abstinence is defined on a weekly basis as no urine positive of methamphetamine (or amphetamine) and self-report of not use for the 7 day period. Secondary measures include treatment retention, drug craving, mood, and safety.

Key facts

Study ID

NCT00571922

Run by

NYU Langone Health

People needed

72

Starts

2007-07-01

Expected to finish

2008-11-01

Last updated by the study team

2017-03-24

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Methamphetamine dependence
• Treatment seeking
• Urine sample (+) for methamphetamine

You may not qualify if…

• Pregnancy
• Dependence on other drugs (except nicotine)
• DSM-IV axis I disorder unrelated to drug abuse
• Serious medical condition in clinicians opinion.
• AIDs
• Untreated syphilis
• Allergy to acamprosate
• Methadone, or other ORP, maintenance

Where it is running

• VA New York Harbor Healthcare System, MHAD clinic — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.